多价肺炎球菌多糖疫苗
Polyvalent pneumococcal polysaccharide vaccines.
作者信息
Hilleman M R, McLean A A, Vella P P, Weibel R E, Woodhour A F
出版信息
Bull World Health Organ. 1978;56(3):371-5.
A 14-valent pneumococcal vaccine has recently been licensed for general use after extensive testing in human subjects. Antibody production was satisfactory in 92% of individuals and a highly significant (76-92%) reduction was found in the rates for pneumococcal pneumonias caused by the capsular types present in the vaccine. Children over 2 years of age respond well to the vaccine, but younger children may not respond satisfactorily to some capsular types. In adults, the duration of the protective effect is at present unknown, but no substantial booster response was seen after a second dose at 1 year. Such a booster dose, in fact, induced a marked increase in the degree of local reaction at the injection site.
一种14价肺炎球菌疫苗最近在经过广泛的人体试验后获得了通用许可。92%的个体抗体产生情况令人满意，并且发现由疫苗中存在的荚膜型引起的肺炎球菌肺炎发病率显著降低（76%-92%）。2岁以上儿童对该疫苗反应良好，但较年幼的儿童对某些荚膜型可能反应不令人满意。在成年人中，目前尚不清楚保护作用的持续时间，但在1年后接种第二剂后未观察到明显的加强反应。事实上，这样的加强剂量导致注射部位局部反应程度明显增加。
Zotero 插件